Tjagvad Christian, Clausen Thomas, Handal Marte, Skurtveit Svetlana
Norwegian Centre for Addiction Research [SERAF], University of Oslo, Kirkeveien 166, Bygg 45, 0407, Oslo, Norway.
Department of Pharmacoepidemiology, Norwegian Institute of Public Health, Oslo, Norway.
BMC Psychiatry. 2016 May 27;16:168. doi: 10.1186/s12888-016-0881-y.
Benzodiazepines are frequently prescribed to patients with drug use disorders. However, it has previously been difficult to distinguish whether this frequent prescribing was due to underlying psychiatric disorders or inappropriate prescribing. In a nationwide cohort study, we investigated the prescribing of benzodiazepines to patients with drug use disorders in connection with treatment admission.
Benzodiazepine prescriptions to patients (N = 33203) aged 18 to 67 years admitting for outpatient treatment for drug use disorders in Denmark, 2000 to 2010, were studied by using linked data from nationwide health registries. Factors associated with increasing amounts of benzodiazepine use within the first year after admission were assessed by multinomial logistic regression. Proportions of very long-term benzodiazepine prescription were calculated.
During the first year after admission to treatment, 26.2 % of patients were prescribed benzodiazepines. Of these, 35.5 % were prescribed benzodiazepines at dose levels that might indicate inappropriate use (>365 Defined Daily Dose per year), and 34.6 % were prescribed more than one type of benzodiazepines. Diazepam was the most commonly prescribed type. Among patients with opioid use, 43.2 % were prescribed benzodiazepines which were three times higher than for patients with cannabis (12.2 %) or central stimulating drugs (13.8 %) as their primary drug use. Admitting to treatment for a drug use disorder did not increase the specialized psychiatric treatment coverage of this patient group, disregarding use of prescribed benzodiazepines. 29.5 % were new users of prescribed benzodiazepines, and of these, 27.5 % continued into very long-term use (≥4 years after admission) during the study period.
Benzodiazepines were commonly prescribed to patients admitting to treatment for drug use disorders, and included prescription of multiple and non-optimal types, high doses, and very long-term prescriptions. These findings point towards inappropriate prescribing of benzodiazepines in many cases more than treatment for psychiatric disorders.
苯二氮䓬类药物经常被开给有药物使用障碍的患者。然而,以前很难区分这种频繁开药是由于潜在的精神疾病还是不适当的开药行为。在一项全国性队列研究中,我们调查了与治疗入院相关的苯二氮䓬类药物对有药物使用障碍患者的处方情况。
利用丹麦全国健康登记处的关联数据,研究了2000年至2010年期间18至67岁因药物使用障碍而接受门诊治疗的患者(N = 33203)的苯二氮䓬类药物处方。通过多项逻辑回归评估入院后第一年内与苯二氮䓬类药物使用量增加相关的因素。计算了长期苯二氮䓬类药物处方的比例。
在入院治疗后的第一年内,26.2%的患者被开具了苯二氮䓬类药物。其中,35.5%的患者所开具的苯二氮䓬类药物剂量水平可能表明使用不当(每年超过365限定日剂量),34.6%的患者被开具了不止一种类型的苯二氮䓬类药物。地西泮是最常被开具的类型。在使用阿片类药物的患者中,43.2%的患者被开具了苯二氮䓬类药物,这是主要使用大麻(12.2%)或中枢兴奋剂(13.8%)的患者的三倍。因药物使用障碍入院治疗并未增加该患者群体的专科精神治疗覆盖率,无论是否使用所开具的苯二氮䓬类药物。29.5%是苯二氮䓬类药物的新使用者,其中27.5%在研究期间持续长期使用(入院后≥4年)。
苯二氮䓬类药物经常被开给因药物使用障碍入院治疗的患者,包括多种且非最佳类型、高剂量和长期处方。这些发现表明在许多情况下,苯二氮䓬类药物的处方是不适当的,而不仅仅是用于精神疾病治疗。